What is TMO's 12-month stock price target?

Thermo Fisher Scientific Inc (TMO) carries a 12-month consensus base price target of $728.73 (+6.8% from $682.65), with a bull-case target of $859.9 and a bear-case floor of $559.77.

Stock Ratings / Industrials / TMO / forecast

DE (70) DHR (69) JCI (69) NOC (67) ⌘ Pro Terminal →

Thermo Fisher Scientific Inc (TMO) 12-Month Stock Forecast & Price Target Cone

Q: Is TMO stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates TMO B (Buy — BUY) with an RQD Confidence score of 73/100.

$682.65 -2.06% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $681.76

Thermo Fisher Scientific Inc (TMO) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (steady margins, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $257.71B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TMO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TMO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Thermo Fisher Scientific Inc (NYSE: TMO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $682.65 (-2.06% 1D, market cap $257.71B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 11/20. Across 486 tracked Industrials issuers, TMO ranks #21 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TMO compare to DE and DHR in the Industrials sector?

▼

Within the Industrials sector (Industrial Machinery/Components), TMO carries a Roarable B (73/100 RQD), trailing P/E of 39.0x, gross margin of —, and ROIC of 9.3%. By comparison, DE (Deere & Company) holds a B- grade (70/100 RQD, P/E 35.4x, ROIC 9.3%, cap $182.13B) and DHR (Danaher Corporation) posts a C+ grade (69/100 RQD, P/E 46.1x, ROIC 6.1%, cap $163.38B). Among the 5-stock peer group, NOC leads on earnings multiple (19.1x) while JCI leads on capital efficiency (15.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TMO?

▼

Per TMO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000097745), Thermo Fisher Scientific Inc generated $44.56B in revenue (+3.9% YoY), $6.72B in net income, and $6.29B in free cash flow against $110.34B in total assets and $25.82B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $681.76 (-0.13%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 14.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TMO)Realized 20D OHLCV Swing Band: ±5.9%

Deterministic 5-Pillar Attribution (73/100 Composite)

🔍 WHY TMO SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (26% of score)

20D Institutional Volume Accumulation (±5.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 4.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$673.20+3.1% Next Q

Q2 (-2Q)

Grade B-$694.02+1.5% Next Q

Q3 (-1Q)

Grade B$704.15-3.1% Next Q

Current

Grade B$682.65+7.1% Hist 90D α

Trajectory: C+ (65) → B (73)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TMO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, TMO faces multiple-compression risk if 39.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($659.23) or 200D SMA ($552.63) invalidates the momentum regime and cuts Target Base ($728.73) toward Bear Floor ($559.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TMO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TMO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 73%NO 27%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your TMO Position Size: $10,000

Shares at $682.65: 14.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $559.77

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $728.73

$10,675

+$675 (+6.8%)

12M Bull Case BreakoutTarget $859.90

$12,596

+$2,596 (+26.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 23● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$758	74%	A
Goldman SachsSector Coverage Lead	BUY	$808	69%	B
JP MorganUS Large-Cap Research	HOLD	$644	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (TMO Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TMO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.57%🛡️ HOLDING TREND SUPPORT

2026-11-03O $709.2H $709.2L $682.7C $682.7VOL 2.09M

RES: $728.6SUP: $682.9SMA50: $659.2SMA200: $552.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TMO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TMO Butterfly Map → + Track TMO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

29.8%/yr Implied 5Y Growth

vs. +3.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TMO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

TMO → LLY Confirmed Filing

Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TMO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TMO)

Industrials Rank #21 of 486 ⚔️ DE vs TMO Full Matrix →

1. Head-to-Head Industrials Peer Comparison (TMO vs. DE, DHR, JCI, NOC)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Thermo Fisher Scientific Inc (TMO) ranks #21 by composite RQD confidence (73/100, grade B) and #3 by equity capitalization ($257.71B). Within this direct 5-issuer industry benchmark cohort, NOC leads on earnings valuation at 19.1x trailing P/E, while JCI leads on capital efficiency and profitability with 15.6% ROIC and 36.4% gross margin. TMO currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TMO ACTIVE Thermo Fisher Scientific Inc	B	73/100	39.0x	—	9.3%	-2.06%	$257.71B	Benchmark Subject
DE Deere & Company	B-	70/100	35.4x	—	9.3%	-1.17%	$182.13B	/de-vs-tmo →
DHR Danaher Corporation	C+	69/100	46.1x	59.1%	6.1%	-1.83%	$163.38B	/dhr-vs-tmo →
JCI Johnson Controls International plc Ordinary Share	C+	69/100	29.1x	36.4%	15.6%	-1.70%	$90.27B	/jci-vs-tmo →
NOC Northrop Grumman Corporation	C+	67/100	19.1x	—	13.0%	-0.40%	$79.21B	/noc-vs-tmo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000097745 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Thermo Fisher Scientific Inc (TMO) reported GAAP revenue of $44.56B (+3.9% vs. FY2024 revenue of $42.88B , and +4.0% cumulative change since FY2023) , GAAP net income of $6.72B, operating cash flow of $7.82B, and free cash flow of $6.29B (-13.4% YoY). On the balance sheet, TMO closed FY2025 with $110.34B in total assets against $25.82B in total debt (Altman Z-Score: 4.50, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.56B	$6.72B	$7.82B	$6.29B	$110.34B	$25.82B
FY2024 (FY)	2024-12-31	$42.88B	$6.34B	$8.67B	$7.27B	$97.32B	$22.77B
FY2023 (FY)	2023-12-31	$42.86B	$5.96B	$8.41B	$6.48B	$144.22B	$33.75B

3. TMO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TMO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TMO compare to DE and DHR in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for TMO?

Where is TMO trading relative to its 50-day, 200-day, and 52-week technical levels?

TMO last traded at $682.65 (-2.06% on volume of 1,854,137 shares), positioning the stock +3.55% above its 50-day simple moving average ($659.23) and +23.53% above its 200-day simple moving average ($552.63). Across its 52-week range of $435.27 to $711.85, TMO sits at the 89.4% percentile with a 14-day RSI of 56.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.9% ($642.37 to $722.93).

Direct Sub-Reports: TMO RQD Cockpit TMO 12M Forecast TMO Earnings & Move TMO Dividends & DRIP TMO Insiders & 13F TMO Whale Options TMO Profit Sankey TMO News & Why

ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

TMO — Thermo Fisher Scientific Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Thermo Fisher Scientific Inc (TMO) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $682.65 (-2.06% 1D, market capitalization $257.71B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 9.3%, gross margin of —, operating margin of 17.4%, and free cash flow yield of 2.40%.
Whale 13F & Options Flow (19/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (18/20): Incorporates a 0.94x equity beta, Altman Z-Score of 4.50, Piotroski F-Score of 8/9, and Debt/Equity of 0.42x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Thermo Fisher Scientific Inc is a NYSE-listed issuer classified in the Industrials sector and Industrial Machinery/Components industry. The company operates a sterile fill-finish business within its Biopharma Services segment, which the source links to Eli Lilly's GLP-1 manufacturing needs. FY 2025 revenue was $44.56B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Thermo Fisher Scientific Inc (TMO) reported $44.56B in annual revenue (up from $42.88B in FY2024, +3.9% YoY) and $6.72B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.86B revenue, $5.96B net income) through FY2025, TMO scaled operating cash flow to $7.82B and free cash flow to $6.29B, backed by $110.34B in total assets against $25.82B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $435.27 – $711.85 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 39.0x trailing P/E and 30.4x EV/EBITDA against 17.4% operating margins and a 0.94x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

TMO's principal upstream-to-downstream dependency is in sterile fill-finish: capacity constraints at contract manufacturing sites flow through to GLP-1 drug makers such as Eli Lilly. The investor implication is a second-order bottleneck dynamic: if validation timelines for new lines are long (18–36 months), near-term capacity remains tight and supports pricing and volume for incumbents, but the same timeline means any shortfall in capacity is slow to correct. The competing explanation, that a large drug maker internalizes fill-finish, is the main second-order risk, because it would redirect volume away from TMO over time.94.

Key Question #1: Can TMO sustain or expand its 17.4% operating margin and 9.3% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $44.56B and free cash flow of $6.29B, how will capital allocation balance growth reinvestment against $25.82B in total debt?
Key Question #3: How sensitive is TMO's 36.3x forward P/E multiple to Industrials capital spending cycles and macro interest-rate shifts (Beta 0.94x)?

TMO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Thermo Fisher Scientific Inc (TMO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TMO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Thermo Fisher Scientific's Q3 2026 Earnings: What to Expect